09/24/2026
BREAKING: New Nanotherapy Shows Promise Against Endometriosis
Researchers at Washington State University have developed a targeted nanotherapy that showed promising results against endometriosis in early preclinical research.
The treatment uses nanoparticles to deliver niclosamide, an existing drug, directly to a specific type of immune cell linked to endometriosis.
In mouse models, a single dose of the experimental treatment reduced the number and size of endometriosis lesions and also decreased pain sensitivity associated with the disease.
The researchers designed the nanotherapy to target FRβ positive macrophages, immune cells that appear to contribute to inflammation and disease progression in endometriosis. The nanoparticle system also improves the water solubility of niclosamide and allows the drug to be released inside the targeted cells.
Endometriosis affects approximately 1 in 10 women of reproductive age, or around 190 million people worldwide. The condition can cause chronic pelvic pain, painful periods, pain during s*x, and infertility.
Current treatments include hormonal therapies and surgery, but these approaches can have limitations, side effects, and recurrence of symptoms.
The new approach is particularly notable because it is designed as a non hormonal, targeted treatment rather than a therapy that broadly affects the reproductive hormones.
However, this is still an early stage discovery. The results so far come from animal studies, and the researchers are continuing work toward future human clinical trials.
If successful in humans, targeted drug delivery could potentially offer a more precise approach to treating endometriosis.
Source: Washington State University, 2026; Advanced Healthcare Materials.
Follow for more please StayHure.
